Key facts
- It has raised $15.2M; the latest was PE Growth/Expansion ($5.0M) in Feb 2025.
- Notable investors include Advantage Capital (Louisiana), Community Development Venture Capital Alliance.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Gravity Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Gravity Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gravity Diagnostics
Provider of pharmacogenomics diagnostic services intended to serve physicians to mitigate drug abuse and addiction related to controlled substances. The company offers testing for toxicology, pharmacogenomics, and infectious diseases, enabling clients to prescribe medications with precise dosing for improved patient outcomes.
- Sector
- Healthcare
- HQ
- Covington, KY, United States
- Founded
- 2016
- Employees
- 215
- Website
- gravitydiagnostics.com/
- Ownership
- Privately Held (backing)
Gravity Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gravity Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gravity Diagnostics in its N-PORT filings yet. We sweep new filings monthly.